+

WO2007031878A3 - Methodes de traitement de troubles nerveux - Google Patents

Methodes de traitement de troubles nerveux Download PDF

Info

Publication number
WO2007031878A3
WO2007031878A3 PCT/IB2006/003503 IB2006003503W WO2007031878A3 WO 2007031878 A3 WO2007031878 A3 WO 2007031878A3 IB 2006003503 W IB2006003503 W IB 2006003503W WO 2007031878 A3 WO2007031878 A3 WO 2007031878A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
disease
treating
nervous disorders
treating nervous
Prior art date
Application number
PCT/IB2006/003503
Other languages
English (en)
Other versions
WO2007031878A2 (fr
Inventor
Laurent Desire
Betrand Leblond
Eric Beausoleil
Thierry Taverne
Fabien Schweighoffer
Virginie Picard
Original Assignee
Exonhit Therapeutics Sa
Laurent Desire
Betrand Leblond
Eric Beausoleil
Thierry Taverne
Fabien Schweighoffer
Virginie Picard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exonhit Therapeutics Sa, Laurent Desire, Betrand Leblond, Eric Beausoleil, Thierry Taverne, Fabien Schweighoffer, Virginie Picard filed Critical Exonhit Therapeutics Sa
Priority to EP06831657A priority Critical patent/EP1951247A2/fr
Priority to CA002616237A priority patent/CA2616237A1/fr
Priority to US11/989,396 priority patent/US20090093471A1/en
Publication of WO2007031878A2 publication Critical patent/WO2007031878A2/fr
Publication of WO2007031878A3 publication Critical patent/WO2007031878A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des compositions et des méthodes pour traiter des troubles nerveux. L'invention concerne plus particulièrement des méthodes de traitement de troubles liés au peptide bêta-amyloïde, notamment la maladie d'Alzheimer, au moyen d'inhibiteurs de Rac1. L'invention peut être appliquée à des sujets mammifères, en particulier des sujets humains, à différents stades de la maladie, notamment au début de la maladie. L'invention concerne également des procédés de production, d'identification, de sélection ou d'optimisation de composés à utiliser dans le traitement de troubles liés au peptide bêta-amyloïde, ces procédés consistant notamment à déterminer l'aptitude d'un composé d'essai à inhiber Rac1.
PCT/IB2006/003503 2005-07-27 2006-07-26 Methodes de traitement de troubles nerveux WO2007031878A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06831657A EP1951247A2 (fr) 2005-07-27 2006-07-26 Methodes de traitement de troubles nerveux
CA002616237A CA2616237A1 (fr) 2005-07-27 2006-07-26 Methodes de traitement de troubles nerveux
US11/989,396 US20090093471A1 (en) 2005-07-27 2006-07-26 Methods of Treating Nervous Disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/190,070 2005-07-27
US11/190,070 US20070027146A1 (en) 2005-07-27 2005-07-27 Methods of treating nervous disorders

Publications (2)

Publication Number Publication Date
WO2007031878A2 WO2007031878A2 (fr) 2007-03-22
WO2007031878A3 true WO2007031878A3 (fr) 2007-09-07

Family

ID=37695181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/003503 WO2007031878A2 (fr) 2005-07-27 2006-07-26 Methodes de traitement de troubles nerveux

Country Status (4)

Country Link
US (2) US20070027146A1 (fr)
EP (1) EP1951247A2 (fr)
CA (1) CA2616237A1 (fr)
WO (1) WO2007031878A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070027146A1 (en) * 2005-07-27 2007-02-01 Exonhit Therapeutics Sa Methods of treating nervous disorders
CA2638887A1 (fr) * 2006-02-01 2007-08-09 Exonhit Therapeutics Sa Methodes pour traiter des troubles degeneratifs avec un inhibiteur de rac1b
US20110009475A1 (en) * 2007-07-13 2011-01-13 Massachusetts Institute Of Technology Methods for treating stress induced emotional disorders
US20100041653A1 (en) * 2008-08-15 2010-02-18 Burnham Institute For Medical Research Composition and methods for the design and development of metallo-enzyme inhibitors
ES2377086B1 (es) * 2010-02-25 2013-07-01 Universidad Del Pais Vasco Compuestos para el tratamiento de alzheimer.
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
WO2014170712A1 (fr) 2013-04-15 2014-10-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiteurs de rac-1 ou inhibiteurs de pi3k pour la prévention d'un dysfonctionnement de la barrière intestinale
US10155001B2 (en) 2013-06-14 2018-12-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) RAC1 inhibitors for inducing bronchodilation
JP2017524739A (ja) 2014-07-17 2017-08-31 アンセルムＩｎｓｅｒｍ 神経筋接合部関連疾患の処置方法
WO2016207366A1 (fr) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques de traitement d'infections virales
CN109925510A (zh) * 2019-04-11 2019-06-25 北京卓凯生物技术有限公司 Rac1活性抑制剂在制备治疗阿尔茨海默病的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076445A2 (fr) * 2003-02-28 2004-09-10 Exonhit Therapeutics Sa Nouveaux composes et procedes de traitement de pathologies associees a la proliferation cellulaire, de retinopathies et de l'arthrite

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053223B2 (en) * 2003-02-14 2006-05-30 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
WO2005051392A1 (fr) * 2003-11-20 2005-06-09 Children's Hospital Medical Center Inhibiteurs de gtpase et procedes d'utilisation correspondants
US20070027146A1 (en) * 2005-07-27 2007-02-01 Exonhit Therapeutics Sa Methods of treating nervous disorders
US20070093471A1 (en) * 2005-10-26 2007-04-26 Alamo Pharmaceuticals, Llc Compositions and methods for the administration clozapine formulations which modulate body weight

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076445A2 (fr) * 2003-02-28 2004-09-10 Exonhit Therapeutics Sa Nouveaux composes et procedes de traitement de pathologies associees a la proliferation cellulaire, de retinopathies et de l'arthrite

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DESIRE L. ET AL.: "RAC1 Inhibition Targets APP Processing by .gamma.-Secretase and Decreases A.beta. Production in vitro and in Vivo", JOURNAL OF BIOLOGICAL CHEMISTRY, 8 September 2005 (2005-09-08), pages 1 - 26, XP002429521, Retrieved from the Internet <URL:http://www.jbc.org/cgi/reprint/M507913200v1.pdf> [retrieved on 20070416] *
GIANNI D ET AL: "Platelet-derived growth factor induces the beta-gamma-secretase-medi ated cl eavage of Alzheimer's amyloid precursor protein through a Src-Rac-dependent pathway", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 278, no. 11, 14 March 2003 (2003-03-14), pages 9290 - 9297, XP002282954, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
US20070027146A1 (en) 2007-02-01
EP1951247A2 (fr) 2008-08-06
CA2616237A1 (fr) 2007-03-22
US20090093471A1 (en) 2009-04-09
WO2007031878A2 (fr) 2007-03-22

Similar Documents

Publication Publication Date Title
WO2007031878A3 (fr) Methodes de traitement de troubles nerveux
SI2527315T1 (sl) Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
WO2006044497A3 (fr) Composes de spiropiperidine utilises comme inhibiteurs de beta-secretase en vue du traitement de la maladie d&#39;alzheimer
WO2004065576A3 (fr) Methodes et compositions de traitement de troubles urologiques a l&#39;aide de genes 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579, 15985, 15625, 760, 18603,
WO2006093348A3 (fr) Procede et composition destines au traitement des maladies vasculaires peripheriques
WO2005004802A3 (fr) Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d&#39;alzheimer
WO2005032471A3 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d&#39;alzheimer
EP1737453A4 (fr) Procedes d&#39;utilisation et compositions comprenant des composes destines au traitement et a la gestion de maladies ou de troubles de la peau
WO2006071778A3 (fr) Traitement de la maladie de parkinson et de troubles associes au moyen de cellules derivees postnatales
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
WO2004103959A3 (fr) Composés hétérocycliques et utilisations
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d&#39;alzheimer
WO2007011833A3 (fr) Inhibiteurs de spiropiperidine beta-secretase pour le traitement de la maladie d&#39;alzheimer
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2007014943A3 (fr) Traitement pour maladies neurologiques
WO2005051914A8 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d&#39;alzheimer
WO2007109107A3 (fr) Atf4 utilisé comme cible thérapeutique dans la maladie d&#39;alzheimer et autres troubles neurologiques
EP1786428A4 (fr) Compositions d&#39;inhibiteur pde5 et methodes de traitement des troubles cardiaques
PL377715A1 (pl) Antagoniści CCR1 do leczenia między innymi demielizacyjnej choroby zapalnej
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
WO2006057945A3 (fr) Derives pyridyle 2,3,4,6-substitues utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d&#39;alzheimer
WO2004063340A3 (fr) Methodes et compositions pour traiter les maladies cardio-vasculaires au moyen de genes 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612,
DE602004019500D1 (en) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer
WO2009016231A3 (fr) Compositions et procédés permettant de détecter des troubles liés à l&#39;histamine
WO2003073983A3 (fr) Methodes et compositions de traitement de la douleur et des troubles douloureux a l&#39;aide des molecules 9949, 14230, 760, 62553, 41897, 47174, 33408, 10002,16209, 314, 636, 27410, 33260, 619,15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 9569 ou 13424

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006831657

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2616237

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11989396

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06831657

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006831657

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载